CYTOTOXICITY AND ANTIMICROBIAL ACTIVITY OF MONO-, DI- AND TRINUCLEAR RUTHENIUM(II) POLYPYRIDINE COMPLEXES

Objectives: To evaluate the in vitro cytotoxicity, antibacterial and antifungal activity of the synthesized mono-, di- and trinuclear ruthenium(II) polypyridine complexes.Methods: A series of synthesized ruthenium(II) complexes, R1, R2 and R3, are screened for in vitro antiproliferative activity against HepG2 cancer cell line using 96-well plate method. An assay of antimicrobial activity was performed by disc diffusion method. In addition an assay of an antifungal was performed by broth micro-dilution method.Results: The cytotoxicity of complexes revealed IC50 values of 14.52 (R3), 19.53 (R2) and 22.32 μM (R1) against HepG2 cell line in a dose dependent manner. All the complexes inhibited moderately the growth of Gram positive bacteria (G+) such as Staphylococcus aureus (MRSA), Eubacterium lentum, and Bacillus subtillis, quite meagerly the growth of the Gram negative bacterium (G─), Enterobacter aerogenes, but did not inhibit at all the growth of Erwinia amylovora (MTCC 2760) and showed a slight antifungal activity.Conclusion: From this study, we could suggest that the systematic increase in number of imidazole moiety along with expanding cloud of conjugated Ï€-electron system of ruthenium(II) polypyridine complexes is responsible for the antiproliferative activity which increases in the order, R1 < R2 < R3 against HepG2 cancer cells. Consecutively, the complexes show good antimicrobial activity against Gram positive bacteria, but show poor or no effect against Gram negative bacteria and exhibit a little antifungal activity.Â

Neurodevelopmental disorders in children aged 2-9 years: Population-based burden estimates across five regions in India.

BACKGROUND: Neurodevelopmental disorders (NDDs) compromise the development and attainment of full social and economic potential at individual, family, community, and country levels. Paucity of data on NDDs slows down policy and programmatic action in most developing countries despite perceived high burden. METHODS AND FINDINGS: We assessed 3,964 children (with almost equal number of boys and girls distributed in 2-<6 and 6-9 year age categories) identified from five geographically diverse populations in India using cluster sampling technique (probability proportionate to population size). These were from the North-Central, i.e., Palwal (N = 998; all rural, 16.4% non-Hindu, 25.3% from scheduled caste/tribe [SC-ST] [these are considered underserved communities who are eligible for affirmative action]); North, i.e., Kangra (N = 997; 91.6% rural, 3.7% non-Hindu, 25.3% SC-ST); East, i.e., Dhenkanal (N = 981; 89.8% rural, 1.2% non-Hindu, 38.0% SC-ST); South, i.e., Hyderabad (N = 495; all urban, 25.7% non-Hindu, 27.3% SC-ST) and West, i.e., North Goa (N = 493; 68.0% rural, 11.4% non-Hindu, 18.5% SC-ST). All children were assessed for vision impairment (VI), epilepsy (Epi), neuromotor impairments including cerebral palsy (NMI-CP), hearing impairment (HI), speech and language disorders, autism spectrum disorders (ASDs), and intellectual disability (ID). Furthermore, 6-9-year-old children were also assessed for attention deficit hyperactivity disorder (ADHD) and learning disorders (LDs). We standardized sample characteristics as per Census of India 2011 to arrive at district level and all-sites-pooled estimates. Site-specific prevalence of any of seven NDDs in 2-<6 year olds ranged from 2.9% (95% CI 1.6-5.5) to 18.7% (95% CI 14.7-23.6), and for any of nine NDDs in the 6-9-year-old children, from 6.5% (95% CI 4.6-9.1) to 18.5% (95% CI 15.3-22.3). Two or more NDDs were present in 0.4% (95% CI 0.1-1.7) to 4.3% (95% CI 2.2-8.2) in the younger age category and 0.7% (95% CI 0.2-2.0) to 5.3% (95% CI 3.3-8.2) in the older age category. All-site-pooled estimates for NDDs were 9.2% (95% CI 7.5-11.2) and 13.6% (95% CI 11.3-16.2) in children of 2-<6 and 6-9 year age categories, respectively, without significant difference according to gender, rural/urban residence, or religion; almost one-fifth of these children had more than one NDD. The pooled estimates for prevalence increased by up to three percentage points when these were adjusted for national rates of stunting or low birth weight (LBW). HI, ID, speech and language disorders, Epi, and LDs were the common NDDs across sites. Upon risk modelling, noninstitutional delivery, history of perinatal asphyxia, neonatal illness, postnatal neurological/brain infections, stunting, LBW/prematurity, and older age category (6-9 year) were significantly associated with NDDs. The study sample was underrepresentative of stunting and LBW and had a 15.6% refusal. These factors could be contributing to underestimation of the true NDD burden in our population. CONCLUSIONS: The study identifies NDDs in children aged 2-9 years as a significant public health burden for India. HI was higher than and ASD prevalence comparable to the published global literature. Most risk factors of NDDs were modifiable and amenable to public health interventions

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death. Methods: This 1:1 propensity score matched cohort study from 647 public health clinics in Malaysia included all patients with COVID-19 with positive tests aged 18 years and older, who were eligible for nirmatrelvir-ritonavir treatment within 5 days of illness from July 14, 2022, to November 14, 2022. The exposed group was patients with COVID-19 initiated with nirmatrelvir-ritonavir treatment, whereas those not initiated with the drug served as the control group. Data was analyzed from July 14, 2022 to December 31, 2022. Results: A total of 20,966 COVID-19 high-risk outpatients (n = 10,483 for nirmatrelvir-ritonavir group and n = 10,483 for control group) were included in the study. Nirmatrelvir-ritonavir treatment was associated with a 36% reduction (adjusted hazard ratio 0.64 [95% CI 0.43, 0.94]) in hospitalization compared with those not given the drug. There was a single ICU admission for the control group and one death each was reported in the nirmatrelvir-ritonavir and control group, respectively. Conclusions: Nirmatrelvir-ritonavir treatment was associated with reduced hospitalization in high-risk patients with COVID-19 even in highly vaccinated populations

Study recruitment profile.

<p>Study recruitment profile.</p

Multivariable logistic regression analysis for risk factors for NDDs^#.

<p>Multivariable logistic regression analysis for risk factors for NDDs<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002615#t005fn001" target="_blank">^#</a>.</p

Background characteristics of study participants.

<p>Background characteristics of study participants.</p

Prevalence estimates of NDDs for the five study districts according to age categories^*.

<p>Prevalence estimates of NDDs for the five study districts according to age categories^{<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002615#t004fn001" target="_blank">*</a>}.</p